PO.SHP01.02 · 科学与健康政策
Project Cure CRC：一个由患者驱动的生态系统，整合数据、发现并加速结直肠癌的治愈进程
Project Cure CRC: A patient-powered ecosystem uniting data, discovery and accelerating cures for colorectal cancer
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：尽管分子和免疫学科学取得了重大进展，结直肠癌（CRC）仍然是癌症死亡的主要原因之一。研究基础设施的碎片化、多样化人群代表性不足，以及从发现到临床诊疗之间缺乏协调的转化，限制了进展。Colorectal Cancer Alliance于2023年启动了Project Cure CRC，旨在通过研究加速、数据整合、患者赋能和协作伙伴关系，构建一个将患者、研究者和合作伙伴联合起来的全国性生态系统。Project Cure CRC的目标是改善结直肠癌的总生存期并推进新疗法的发展。
方法：Project Cure CRC包含若干此前从未在结直肠癌领域组合使用过的组成部分：1）K-SPY，一项评估结直肠癌围手术期、新辅助及微小残留病灶（MRD）干预措施的适应性平台试验；2）BlueLake，一个连接临床、基因组和患者报告结局数据的数据与真实世界证据平台，为研究和诊疗提供依据；3）BlueHQ，一个数字化的患者支持、导航和参与枢纽，使患者能够彼此联系并与患者导航员沟通，贡献纵向数据，获取量身定制的教育资源，并参与研究机会；以及4）一项以加速朝向治愈的转化进展为重点的竞争性征集提案（RFP）：早期职业研究者奖、资深研究者奖、试点奖和团队科学奖。每份提案均经过同行评审，并被设计为向前反馈至正在进行的K-SPY和BlueLake工作中，从而确保将发现快速转化为临床应用价值。
结果：自启动以来，Project Cure CRC已收到525余份提案，并已向33个项目分配了超过1500万美元的资金，推进了多中心生物标志物和公平性研究，并最终确定了K-SPY提交给FDA的治理框架。目前已有超过150名学术研究者、20个行业合作伙伴以及众多患者参与者参与其中，形成了美国最大的慈善性CRC研究网络。2025年，该联盟成立了一个由多样化结直肠癌患者群体组成的患者咨询委员会，为该生态系统提供反馈。
结论：Project Cure CRC展示了一个可扩展的、由患者驱动的模式，将发现研究、适应性临床试验和真实世界数据整合在一个协调统一的生态系统之中。通过协调研究加速、数据整合、患者赋能和协作伙伴关系，该倡议正在变革结直肠癌研究并加速治愈进程。
查看英文原文 English abstract
Background: Colorectal cancer (CRC) remains a leading cause of cancer mortality despite significant advances in molecular and immunologic science. Progress is limited by fragmented research infrastructure, underrepresentation of diverse populations, and a lack of coordinated translation between discovery and clinical care. The Colorectal Cancer Alliance launched Project Cure CRC in 2023 to build a national ecosystem that unites patients, investigators, and partners through research acceleration, data integration, patient empowerment, and collaborative partnerships. Project Cure CRC's goal is to improve overall survival from colorectal cancer and advance new therapies.
Methods: Project Cure CRC has several components that have never been combined before for colorectal cancer: 1) K-SPY, an adaptive platform trial evaluating perioperative, neoadjuvant, and minimal residual disease (MRD) interventions in colorectal cancer; 2) BlueLake, a data and real-world evidence platform connecting clinical, genomic, and patient-reported outcomes data to inform research and care delivery; 3) BlueHQ, a digital patient support, navigation, and engagement hub enabling patients to connect with each other and patient navigators, contribute longitudinal data, access tailored educational resources, and participate in research opportunities; and 4) A competitive request for proposals (RFPs) focused on accelerating translational progress towards a cure: Early-Career Investigator Awards, Senior Investigator Awards, Pilot Awards, and Team Science Awards. Each proposal is peer-reviewed and designed to feed forward into ongoing K-SPY and BlueLake efforts, ensuring rapid translation of discovery into clinical utility.
Results: Since its launch, Project Cure CRC has received 525+ proposals and has distributed over $15 million in funding across 33 projects, advanced multicenter biomarker and equity studies, and finalized governance frameworks for K-SPY submission to the FDA. More than 150 academic investigators, 20 industry partners, and patient participants are now engaged, forming the largest philanthropic CRC research network in the United States. In 2025, the Alliance launched a patient advisory council consisting of a diverse group of colorectal cancer patients to provide feedback on the ecosystem.
Conclusions: Project Cure CRC demonstrates a scalable, patient-powered model that connects discovery research, adaptive clinical trials, and real-world data within a single coordinated ecosystem. By aligning research acceleration, data integration, patient empowerment, and collaborative partnerships, the initiative is transforming colorectal cancer research and accelerating cures.
利益披露 Disclosure
K. Newcomer, None..
T. Hyams, None..
T. Zeff, None..
M. Mason, None..
D. Fenstermacher, None..
M. Sapienza, None..
E. Siegel, None.